Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Conrad

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Msystems|June 25, 2020
High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic TherapyRuma Raghuvanshi, Karla Vasco, Yoshiki Vázquez-Baeza, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2015
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsJ Stuart Elborn, David E Geller, Douglas Conrad, et al.
The ISME Journal|May 21, 2022
Complex and unexpected outcomes of antibiotic therapy against a polymicrobial infectionLydia-Ann J Ghuneim, Ruma Raghuvanshi, Kerri A Neugebauer, et al.
BMJ Open Respiratory Research|September 20, 2022
Integrating specialist palliative care to improve care and reduce suffering: cystic fibrosis (InSPIRe:CF) - study protocol for a multicentre randomised clinical trialJane Lowers, Elisabeth P Dellon, Anne Stephenson, et al.
The ISME Journal|June 14, 2025
Microenvironmental Effects of a Non-Antibiotic Therapy for a Chronic Polymicrobial Infection Alter Microbial Physiology, Competition, and VirulenceCely T González, Christian Martin, Maddey Crane, et al.
Research Square|May 7, 2026
Antibiotic resistant Achromobacter xylosoxidans are highly susceptible to bacteriophages and often are killed synergistically by phage/antibiotic combinationsDavid Pride, Manola Orlatti, Norhan Turki, et al.
Clinical Drug Investigation|November 14, 2019
Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic FibrosisCarla Cristina Souza Gomez, Paloma Lopes Francisco Parazzi, Karl Jan Clinckspoor, et al.
Trials|December 28, 2022
Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trialPranita D Tamma, Maria Souli, Michael Billard, et al.
NPJ Genomic Medicine|October 31, 2023
Returning incidentally discovered Hepatitis C RNA-seq results to COPDGene study participantsEdwin K Silverman, Arthur Y Kim, Barry J Make, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|November 12, 2019
COPDGene<sup>®</sup> 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary DiseaseKatherine E Lowe, Elizabeth A Regan, Antonio Anzueto, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Msystems|June 25, 2020
High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic TherapyRuma Raghuvanshi, Karla Vasco, Yoshiki Vázquez-Baeza, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2015
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsJ Stuart Elborn, David E Geller, Douglas Conrad, et al.
The ISME Journal|May 21, 2022
Complex and unexpected outcomes of antibiotic therapy against a polymicrobial infectionLydia-Ann J Ghuneim, Ruma Raghuvanshi, Kerri A Neugebauer, et al.
BMJ Open Respiratory Research|September 20, 2022
Integrating specialist palliative care to improve care and reduce suffering: cystic fibrosis (InSPIRe:CF) - study protocol for a multicentre randomised clinical trialJane Lowers, Elisabeth P Dellon, Anne Stephenson, et al.
The ISME Journal|June 14, 2025
Microenvironmental Effects of a Non-Antibiotic Therapy for a Chronic Polymicrobial Infection Alter Microbial Physiology, Competition, and VirulenceCely T González, Christian Martin, Maddey Crane, et al.
Research Square|May 7, 2026
Antibiotic resistant Achromobacter xylosoxidans are highly susceptible to bacteriophages and often are killed synergistically by phage/antibiotic combinationsDavid Pride, Manola Orlatti, Norhan Turki, et al.
Clinical Drug Investigation|November 14, 2019
Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic FibrosisCarla Cristina Souza Gomez, Paloma Lopes Francisco Parazzi, Karl Jan Clinckspoor, et al.
Trials|December 28, 2022
Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trialPranita D Tamma, Maria Souli, Michael Billard, et al.
NPJ Genomic Medicine|October 31, 2023
Returning incidentally discovered Hepatitis C RNA-seq results to COPDGene study participantsEdwin K Silverman, Arthur Y Kim, Barry J Make, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|November 12, 2019
COPDGene<sup>®</sup> 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary DiseaseKatherine E Lowe, Elizabeth A Regan, Antonio Anzueto, et al.
Pageof 5